Show simple item record

dc.contributor.authorThornber, K
dc.contributor.authorKirchhelle, C
dc.date.accessioned2022-09-15T08:49:42Z
dc.date.issued2022-08-02
dc.date.updated2022-09-14T15:51:00Z
dc.description.abstractIn the wake of COVID-19, antimicrobial resistance (AMR) has become termed the 'silent pandemic', with a growing number of editorials warning that international momentum for AMR mitigation is being lost amidst the global turmoil of COVID-19, economic crises and the climate emergency. Yet, is it sufficient to now simply turn the volume of the pre-existing AMR policy discourse back up? Although existing AMR initiatives have previously achieved high levels of international attention, their impact remains limited. We believe it is time to critically reflect on the achievements of the past 7 years and adapt our AMR policies based on the substantial literature and evidence base that exists on the socioecological drivers of AMR. We argue that developing a more sustainable and impactful response requires a shift away from framing AMR as a unique threat in competition with other global challenges. Instead, we need to move towards an approach that emphasizes AMR as inherently interlinked and consciously hardwires upstream interventions into broader global developmental agendas.en_GB
dc.description.sponsorshipUniversity of Exeteren_GB
dc.description.sponsorshipWellcome Trusten_GB
dc.description.sponsorshipNorwegian Research Councilen_GB
dc.identifier.citationVol. 4(4), article dlac083en_GB
dc.identifier.doihttps://doi.org/10.1093/jacamr/dlac083
dc.identifier.urihttp://hdl.handle.net/10871/130839
dc.language.isoenen_GB
dc.publisherOxford University Press (OUP) / British Society for Antimicrobial Chemotherapyen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/35928475en_GB
dc.rights© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.en_GB
dc.titleHardwiring antimicrobial resistance mitigation into global policyen_GB
dc.typeArticleen_GB
dc.date.available2022-09-15T08:49:42Z
dc.identifier.issn2632-1823
exeter.place-of-publicationEngland
dc.descriptionThis is the final version. Available on open access from Oxford University Press via the DOI in this recorden_GB
dc.identifier.eissn2632-1823
dc.identifier.journalJAC-Antimicrobial Resistanceen_GB
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_GB
dc.rights.licenseCC BY
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2022-08-02
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2022-09-15T08:47:08Z
refterms.versionFCDVoR
refterms.dateFOA2022-09-15T08:49:55Z
refterms.panelAen_GB
refterms.dateFirstOnline2022-08-02


Files in this item

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's licence is described as © The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.